Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer

Authors

Jiandong Hu
Mengli Jin
Weihong Feng
Barbara Nassif-Rausseo
Alexandre Reuben
Chunhua Ma
Gregory Lizee
Fenge Li

Publication Date

5-14-2025

Journal

Vaccines

DOI

10.3390/vaccines13050521

PMID

40432130

PMCID

PMC12115679

PubMedCentral® Posted Date

5-14-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Malignant tumors represent a significant threat to human health. Among the various therapeutic strategies available, cancer immunotherapy-encompassing adoptive cell transfer (ACT) and immune checkpoint blockade therapy-has emerged as a particularly promising approach following surgical resection, radiotherapy, chemotherapy, and molecular targeted therapies. This form of treatment elicits substantial antigen-specific immune responses, enhances or restores anti-tumor immunity, thereby facilitating the control and destruction of tumor cells, and yielding durable responses across a range of cancers, which can lead to the eradication of tumor lesions and the prevention of recurrence. Tumor-infiltrating lymphocytes (TILs), a subset of ACT, are characterized by their heterogeneity and are found within tumor tissues, where they play a crucial role in mediating host antigen-specific immune responses against tumors. This review aims to explore recent advancements in the understanding of TILs biology, their prognostic implications, and their predictive value in therapeutic contexts.

Keywords

tumor-infiltrating lymphocytes, molecular mechanisms, malignant solid tumor, clinical response, prognosis

Published Open-Access

yes

Recommended Citation

Hu, Jiandong; Jin, Mengli; Feng, Weihong; et al., "Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer" (2025). Faculty, Staff and Student Publications. 4778.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4778